Main content

    Multiple Sclerosis Clinical Trials

    Sutter Health participates in clinical trials related to Multiple Sclerosis throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.

    Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
    Description: The primary and secondary objectives of this trial are to characterize the long-term safety and tolerability and long term efficacy of RPC1063 1 mg administered once daily in patients with relapsing multiple sclerosis.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients with relapsing multiple sclerosis (RMS) who completed either of the randomized controlled trials (RPC01-201 or RPC01-301, the “parent trials”) and are eligible according to the enrollment criteria.
    Status: Active and open to enrollment.
    Location: Alta Bates Summit Medical Center
    Contact: Alyssa Ferninando 510-204-1610
    Email: FerinA1@sutterhealth.org

    Title: Mechanistic Studies of Phase III Trial with BAF312 in Secondary Progressive Multiple Sclerosis.
    Description: The primary goal is to test if Siponimod (BAF312) will have dual modulatory effects in the peripheral immune system and CNS: Inhibition of pro-inflammatory Th1 and Th17 cell production, promotion of anti-inflammatory Th2 and Treg cell lineage differentiation, down regulation of IL-17 downstream factors such as eotaxin in serum and CSF, and modulation of the circulating effector and regulatory B cell populations.
    Investigator: Joanna Cooper, MD
    Eligibility: Subjects who are participating in Protocol No. CBAF312A2304 (sponsored by Novartis) are eligible to participate in this mechanistic study.
    Status: Active and closed to enrollment.
    Location: Alta Bates Summit Medical Center
    Contact: Julie Illi, RN, 510-204-1757
    Email: IlliJA@sutterhealth.org

    Title: BAF 312 - A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis.
    Description: This study is designed to provide efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis (SPMS) and to obtain regulatory approval to make BAF312 available for clinical use worldwide.
    Investigator: Joanna Cooper, MD
    Eligibility: The study population will consist of ambulatory patients aged 18 to 60 years with a diagnosis of MS with a secondary progressive disease course.
    Status: Active and closed to enrollment.
    Location: Alta Bates Summit Medical Center
    Contact: Julie Illi, RN, 510-204-1757
    Email: IlliJA@sutterhealth.org

    Title: TOPAZ (LPS13649)_A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409).
    Description: The purpose of this study is to evaluate the long-term safety and efficacy of Alemtuzumab, for the patients already treated with this medicine in preceding clinical trials CAMMS223, CAMMS323 (also known as CARE-MS I), CAMMS32400507 (also known as CARE-MS II), or CAMMS03409.
    Investigator: Joanna Cooper, MD
    Eligibility: Multiple Sclerosis patients who have completed at least 48 months of the Extension Study CAMMS03409.
    Status: Active and closed to enrollment.
    Location: Alta Bates Summit Medical Center
    Contact: Alyssa Ferdinando, 510-204-1610
    Email: FerdinA1@sutterhealth.org

    Title: COMB157G2301_A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.
    Description: This study is designed to provide efficacy, safety and tolerability data for subcutaneous (sc) ofatumumab compared to oral teriflunomide (Aubagio®) in patients with relapsing MS.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients 18-55 who have a history of relapsing Multiple Sclerosis (MS) - either RRMS or SPMS with disease activity.
    Status: New - coming soon.
    Location: Alta Bates Summit Medical Center
    Contact: Julie Illi, 510-204-1757
    Email: IlliJA@sutterhealth.org

    Title: ALK8700-A301_A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis.
    Description: The objectives of this study are to evaluate the long-term safety and tolerability of ALKS 8700 as well as its treatment effect overtime in adults subjects with RRMS.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients 18-65 who have a confirmed diagnosis of relapsing-remitting Multiple Sclerosis (RRMS).
    Status: Active and open to enrollment.
    Location: Alta Bates Summit Medical Center
    Contact: Alyssa Ferdinando, 510-204-1610
    Email: FerdinA1@sutterhealth.org

    Title: A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients.
    Description: The primary purpose of this study is to determine which baseline and yearly response factors predict the clinical disease-free status response in subsequent years. The study will also clarify the effectiveness of Tysabri at establishing and maintaining this overall disease-free state.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients age 18 to 45 with a diagnosis of Relapsing Multiple Sclerosis who test negative for the Anti-JCV antibody and are treatment-naïve to disease-modifying therapy and approved to use Tysabri.
    Status: Active and closed to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Lucinda Casson, 510-204-1757
    Email: CassonL@sutterhealth.org

    Title: A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis (ORATORIO)
    Description: The purpose of this research is to investigate the efficacy of ocrelizumab compared with placebo in patients with primary progressive multiple sclerosis.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients with Primary Progressive Multiple Sclerosis.
    Status: Active and closed to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Lucinda Casson, RN, 510-204-1757
    Email: CassonL@sutterhealth.org

    Title: A Phase II, Multicenter, Unblinded Study to Evaluate the Long-term Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) (OCRE EXT)
    Description: The purpose of this research is to test the efficacy and safety of ocrelizumab, the humanized version of the anti-CD20 antigen monoclonal antibody Rituximab, in patients with relapsing-remitting multiple sclerosis.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients with Relapsing Remitting Multiple Sclerosis.
    Status: Active and closed to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Lucinda Casson, RN, 510-204-1757
    Email: CassonL@sutterhealth.org

    Title: Plegridy™ (peginterferon β-1a) Real World Effectiveness and Safety Observational Program (POP)
    Description: The purpose of this observational study is to find out more about the long-term safety and effectiveness of Plegridy, which has been approved by the FDA, over approximately a five year time period.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients 18 and older with RMS who has been newly prescribed Plegridy (or who participated in Study 105MS302 or Study 105MS303) and who is willing and able to complete PROs with minimal assistance
    Location: Alta Bates Summit Medical Center
    Contact: Julie Illi, RN, 510-204-1757
    Email: IlliJA@sutterhealth.org

    > See All Neurology Clinical Trials by Condition